Person:
TÜRK, HACI MEHMET

Profile Picture
Status
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
HACI MEHMET
Last Name
TÜRK
Name
Email Address
Birth Date

Filters

2010 - 2019152020 - 202238
Reset filters

Settings

Type: Article ×

Search Results

Now showing 1 - 10 of 53
  • No Thumbnail Available
    PublicationMetadata only
    Relationship between KRAS mutation and diffusion weighted imaging in colorectal liver metastases; Preliminary study.
    (2020-02-25T00:00:00Z) Türk, HM; Gültekin, MEHMET ALİ; Uysal, Ö; Beşiroğlu, M; Yilmaz, TF; Yurtsever, I; GÜLTEKİN, MEHMET ALİ; TÜRK, HACI MEHMET; TOPRAK, HÜSEYİN; YURTSEVER, İSMAİL; YILMAZ, TEMEL FATİH; SHARIFOV, RASUL; UYSAL, ÖMER
    Purpose: We aimed to investigate whether there are any differences in apparent diffusion coefficient (ADC) values obtained from colorectal liver metastases (CRLM) according to Kirsten rat sarcoma (KRAS) gene mutation status.
  • Thumbnail Image
    PublicationOpen Access
    Multiple myeloma mimicking metastatic lung cancer
    (2015-01-01) Furuncuoglu, Yavuz; Cirak, Yalcin; Turk, HACI MEHMET; BASAR, Melih; Ortapamuk, Hulya; KAUR, Ahmet Cemil; TÜRK, HACI MEHMET
    Multiple myeloma is a hematological malignancy characterized by a clonal proliferation of plasma cells in the bone marrow. Extramedullary dissemination of multiple myeloma is uncommon. Only in rare cases, the malignant plasma cells of multiple myeloma had infiltrated the lung parenchyma. In this case report, we presented a case of multiple myeloma with lung plasmacytoma, in a 42-year-old patient, hospitalized for pain and infiltrative mass in the right lung. The results of his initial evaluation with computed tomography and positron emission tomograpy scanning, resembled lung tumor with bone metastasis. Surprisingly, biopsies from lung tumor and bone metastasis, revealed malignant plasma cells. We found M spike in protein electrophoresis and lambda monoclonal band in immune electrophoresis. A bone marrow biopsy evaluation was done and justified multiple myeloma diagnosis before hematology referral. Multiple myeloma diagnosis at the age of 42 is quite rare.
  • Thumbnail Image
    PublicationOpen Access
    Report of a Case of Signet Ring Carcinoma Presenting as Gastric Mucosal Thickening: A Diagnostic Dilemma
    (2021-01-01T00:00:00Z) Karatoprak, Cumali; Akçakaya, Adem; Şentürk, Hakan; Çoban, Ganime; Şahin, Nurhan; Türk, Hacı Mehmet; KARATOPRAK, CUMALİ; AKÇAKAYA, ADEM; ŞENTÜRK, HAKAN; ÇOBAN, GANİME; ŞAHİN, NURHAN; TÜRK, HACI MEHMET
    The number of cancer cases has been increasing worldwide. Early diagnosis and tumor resection remain as the most effective treatments for gastric cancer. However, early diagnosis is not always possible as it is frequently not possible to make treatment decisions without pathologic diagnosis in patients with clinically suspected cancer. This causes delays in diagnosing cancer. We presented a 58 years old woman with gastric signet ring cell carcinoma that could not be diagnosed despite using four different methods of stomach biopsies. We aimed to emphasize that despite the use of advanced methods, if clinical cancer in non-diagnosed cases is suspected, we should be more aggressive for early diagnosis.
  • No Thumbnail Available
    PublicationMetadata only
    Clinicopathological features of gastroenteropancreatic neuroendocrine neoplasms: a retrospective single-center experience
    (2021-03-01T00:00:00Z) ŞEKERCİ, ABDÜSSELAM; TÜRK, HACI MEHMET; DEMİR, Tarık; ŞEKER, Mesut; AKÇAKAYA, Adem; ARICI, Dilek Sema; ŞEKERCİ, ABDÜSSELAM; TÜRK, HACI MEHMET; DEMİR, TARıK; ŞEKER, MESUT; AKÇAKAYA, ADEM; ARICI, DILEK SEMA
  • Thumbnail Image
    PublicationOpen Access
    Diagnostic performance of apparent diffusion coefficient values for the differentiation of intrahepatic cholangiocarcinoma from gastrointestinal adenocarcinoma liver metastases
    (2021-12-22T00:00:00Z) Yilmaz, TEMEL FATİH; Gultekin, Mehmet Ali; Turk, Hacı Mehmet; Cesme, Dilek Hacer; Besiroglu, Mehmet; Simsek, Melih; Toprak, Huseyin; Alkan, ALPAY; YILMAZ, TEMEL FATİH; TÜRK, HACI MEHMET; ÇEŞME, DİLEK HACER; ŞİMŞEK, MELİH; ALKAN, ALPAY; TOPRAK, HÜSEYİN
    Background: We aimed to investigate whether there is a difference between intrahepatic cholangiocarcinoma (IHCC) and liver metastases of gastrointestinal system (GIS) adenocarcinoma in terms of apparent diffusion coefficient (ADC) values. Patients and methods: From January 2018 to January 2020, we retrospectively examined 64 consecutive patients with liver metastases due to gastrointestinal system adenocarcinomas and 13 consecutive IHCC in our hospital's medical records. After exclusions, fifty-three patients with 53 liver metastases and 10 IHCC were included in our study. We divided the patients into two groups as IHCC and liver metastases of GIS adenocarcinoma. For mean apparent diffusion coefficient (ADCmean) values, the region of interests (ROI) was placed in solid portions of the lesions. ADCmean values of groups were compared. Results: The mean age of IHCC group was 62.50 ± 13.49 and mean age of metastases group was 61.15 ± 9.18. ADCmean values were significantly higher in the IHCC group compared to the metastatic group (p < 0.001). ROC curves method showed high diagnostic accuracy (AUC = 0.879) with cut-off value of < 1178 x 10-6 mm2/s for ADCmean (Sensitivity = 90.57, Specificity = 70.0, positive predictive value [PPV] = 94.1, negative predictive value [NPV] = 58.3) in differentiating adenocarcinoma metastases from IHCC. Conclusions: The present study results suggest that ADC values have a potential role for differentiation between IHCC and GIS adenocarcinoma liver metastases which may be valuable for patient management.
  • Thumbnail Image
    PublicationOpen Access
    Diffusion Tensor Imaging Can Discriminate the Primary Cell Type of Intracranial Metastases for Patients with Lung Cancer.
    (2021-03-04T00:00:00Z) Bilgin, Sabriye Sennur; Gultekin, Mehmet Ali; Yurtsever, Ismail; Yilmaz, Temel Fatih; Cesme, Dilek Hacer; Bilgin, Melike; Topcu, Atakan; Besiroglu, Mehmet; Turk, Haci Mehmet; Alkan, ALPAY; Bilgin, Mehmet; GÜLTEKİN, MEHMET ALİ; YURTSEVER, İSMAİL; YILMAZ, TEMEL FATİH; ÇEŞME, DİLEK HACER; TÜRK, HACI MEHMET; ALKAN, ALPAY; BİLGİN, MEHMET
    Purpose: Histopathological differentiation of primary lung cancer is clinically important. We aimed to investigate whether diffusion tensor imaging (DTI) parameters of metastatic brain lesions could predict the histopathological types of the primary lung cancer. Methods: In total, 53 patients with 98 solid metastatic brain lesions of lung cancer were included. Lung tumors were subgrouped as non-small cell carcinoma (NSCLC) (n = 34) and small cell carcinoma (SCLC) (n = 19). Apparent diffusion coefficient (ADC) and Fractional anisotropy (FA) values were calculated from solid enhanced part of the brain metastases. The association between FA and ADC values and histopathological subtype of the primary tumor was investigated. Results: The mean ADC and FA values obtained from the solid part of the brain metastases of SCLC were significantly lower than the NSCLC metastases (P < 0.001 and P = 0.003, respectively). ROC curve analysis showed diagnostic performance for mean ADC values (AUC=0.889, P = < 0.001) and FA values (AUC = 0.677, P = 0.002). Cut-off value of > 0.909 × 10-3 mm2/s for mean ADC (Sensitivity = 80.3, Specificity = 83.8, PPV = 89.1, NPV = 72.1) and > 0.139 for FA values (Sensitivity = 80.3, Specificity = 54.1, PPV = 74.2, NPV= 62.5) revealed in differentiating NSCLC from NSCLC. Conclusion: DTI parameters of brain metastasis can discriminate SCLC and NSCLC. ADC and FA values of metastatic brain lesions due to the lung cancer may be an important tool to differentiate histopathological subgroups. DTI may guide clinicians for the management of intracranial metastatic lesions of lung cancer.
  • Thumbnail Image
    PublicationOpen Access
    The effect of sarcopenia on erlotinib therapy in patients with metastatic lung adenocarcinoma.
    (2022-05-14T00:00:00Z) Topcu, Atakan; Ozturk, Akin; Yurtsever, İSMAİL; Besiroglu, Mehmet; Yasin, Ayse Irem; Turk, Haci Mehmet; Seker, Mesut; YURTSEVER, İSMAİL; TÜRK, HACI MEHMET
    Erlotinib, a tyrosine kinase inhibitor, has been shown to improve the survival of patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer. Sarcopenia is a status with increasing importance in lung cancer, and it may predict a poor prognosis. We aimed to evaluate the impact of sarcopenia on erlotinib therapy and prognosis in patients with EGFR-mutated (exon 19 or 21 L858R) metastatic lung adenocarcinoma. Sarcopenia was defined as skeletal muscle index ≤39 cm2/m2 for women and ≤55 cm2/m2 for men. The patient characteristics, inflammation parameters, clinical and survival outcomes of the erlotinib therapy were examined according to sarcopenia status. We also analyzed the erlotinib treatment-related toxicity. Seventy-two patients were included in our retrospective study, and the mean age of the patients was 63.7 years. A total of 39 (54.2%) patients were diagnosed with sarcopenia. Patients with sarcopenia had a poor prognosis and had a shorter median progression-free survival (PFS) than patients without sarcopenia (10.5 months vs. 21.8 months, p=0.002). Sarcopenia (HR 2.08) and C-reactive protein > 6.5 mg/L (HR 2.57) were determined as independent poor prognostic factors for PFS of erlotinib therapy. Treatment-related toxicity occurred in 34.7% of patients treated with erlotinib, and sarcopenia did not significantly affect treatment-related toxicity. We also found that sarcopenia significantly affected the response to erlotinib. The expected survival outcomes may be low when erlotinib therapy is used in patients with sarcopenia and metastatic lung adenocarcinoma. This study showed that survival and clinical outcomes could be better predicted by detecting sarcopenia in patients with lung cancer using erlotinib.
  • No Thumbnail Available
    PublicationMetadata only
    An unusual presentation of extramedullary plasmacytoma in testis and review of the literature.
    (2010-12-01T00:00:00Z) Turk, HACI MEHMET; KOMURCU, S; OZET, A; KUZHAN, O; GÜNHAN, O; TÜRK, HACI MEHMET
  • No Thumbnail Available
    PublicationMetadata only
    Is the Duration of Temozolomide Predictive for Sequential Bevacizumab Treatment Responses in the Glioblastoma Multiforme Cancer Setting?
    (2021-08-01T00:00:00Z) Besiroglu, Mehmet; Demir, Tarik; Shbair, Abdallah T M; Yasin, Ayse Irem; Topcu, Atakan; Turk, HACI MEHMET; TÜRK, HACI MEHMET
  • Thumbnail Image
    PublicationOpen Access
    Incidental detection of prostate-specific antigen-negative metastatic prostate cancer initially presented with solitary pulmonary nodule on fluorodeoxyglucose positron emission tomography/computed tomography
    (2015-01-01) ERDOĞAN, EZGİ BAŞAK; Buyukpinarbasili, NUR; ZİYADE, SEDAT; AKMAN, Tolga; TÜRK, HACI MEHMET; AYDIN, MEHMET; ERDOĞAN, EZGİ BAŞAK; BÜYÜKPINARBAŞILI, NUR; ZİYADE, SEDAT; TÜRK, HACI MEHMET; AYDIN, MEHMET
    A 71-year-old male patient with solitary pulmonary nodule underwent fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) showing slightly increased FDG uptake in this nodule. In addition, PET/CT detected hypermetabolic sclerotic bone lesions in the right second rib and 7(th) thoracic vertebrae, which were interpreted as possible metastases, and mildly increased FDG uptake in the prostate gland highly suspicious of malignancy. The patient's prostate-specific antigen (PSA) level was within normal range (3.8 ng/dL). The histopathological examination of the lung nodule and right second rib lesion proved metastases from prostate cancer, then the prostate biopsy-confirmed prostate adenocarcinoma. The unique feature of this case is to emphasize the importance of performing PET/CT for solitary pulmonary nodule in detecting PSA-negative metastatic prostate cancer. This case indicated that it should be kept in mind that, even if the PSA is negative, a lung metastasis of prostate cancer may be an underlying cause in patients evaluated for solitary pulmonary nodule by FDG PET/CT.